REPORT ID 2759

EMEA (Europe, Middle East and Africa) Multiple Sclerosis (MS) Drugs Market Report 2019

Publish Date
2019
Pages
111
Format
Electronic (PDF)

In this report, the EMEA Multiple Sclerosis (MS) Drugs market is valued at USD   XX million in 2019 and is expected to reach USD  XX million by the end of 2025, growing at a CAGR of  XX% between 2019 and 2025.

Geographically, this report split EMEA into Europe, the Middle East and Africa, With sales (K Pcs), revenue (Million USD), market share and growth rate of Multiple Sclerosis (MS) Drugs for these regions, from   2019 to 2025 (forecast)
    Europe: Germany, France, UK, Russia, Italy and Benelux;
    Middle East: Saudi Arabia, Israel, UAE and Iran;
    Africa: South Africa, Nigeria, Egypt and Algeria.

EMEA Multiple Sclerosis (MS) Drugs market competition by top manufacturers/players, with Multiple Sclerosis (MS) Drugs sales volume (K Pcs), price (USD/Pcs), revenue (Million USD) and market share for each manufacturer/player; the top players including
    Bayer AG
    Bayhill Therapeutics
    Biogen Idec
    Cinnagen
    Daiichi Sankyo
    Eli Lilly
    Fast Forward Llc
    Antisense Therapeutics
    Apitope
    Five Prime Therapeutics
    Genmab
    Artielle Immunotherapeutics
    Genzyme
    Glaxosmithkline
    Gw Pharmaceuticals
    Innate Immunotherapeutics

On the basis of product, this report displays the sales volume, revenue, product price, market share and growth rate of each type, primarily split into
    Copaxone (Glatiramer Acetate, Copolymer 1)
    Novantrone (Mitoxantrone)
    Gilenya (Fingolimod, Fty720)
    Aubagio (Teriflunomide)
    Tecfidera (Dimethyl Fumarate)
    Firategrast (Sb683699, T-0047)
    Siponimod (Baf312)
    Others

On the basis on the end users/applications, this report focuses on the status and outlook for major applications/end users, sales volume, market share and growth rate for each application, including
    RRMS
    SPMS
    PPMS
    PRMS

If you have any special requirements, please let us know and we will offer you the report as you want.

 
			   
Table of Contents

EMEA (Europe, Middle East and Africa) Multiple Sclerosis (MS) Drugs Market  Report 2019
1 Multiple Sclerosis (MS) Drugs Overview
    1.1 Product Overview and Scope of Multiple Sclerosis (MS) Drugs
    1.2 Classification of Multiple Sclerosis (MS) Drugs
        1.2.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Comparison by Type ( 2014-2024)
        1.2.2 EMEA Multiple Sclerosis (MS) Drugs Market Size (Sales) Market Share by Type (Product Category)  in 2018
        1.2.3 Copaxone (Glatiramer Acetate, Copolymer 1)
        1.2.4 Novantrone (Mitoxantrone)
        1.2.5 Gilenya (Fingolimod, Fty720)
        1.2.6 Aubagio (Teriflunomide)
        1.2.7 Tecfidera (Dimethyl Fumarate)
        1.2.8 Firategrast (Sb683699, T-0047)
        1.2.9 Siponimod (Baf312)
        1.2.10 Others
    1.3 EMEA Multiple Sclerosis (MS) Drugs Market by Application/End Users
        1.3.1 EMEA Multiple Sclerosis (MS) Drugs Sales (Volume) and Market Share Comparison by Application ( 2014-2024
        1.3.2 RRMS
        1.3.3 SPMS
        1.3.4 PPMS
        1.3.5 PRMS
    1.4 EMEA Multiple Sclerosis (MS) Drugs Market by Region
        1.4.1 EMEA Multiple Sclerosis (MS) Drugs Market Size (Value) Comparison by Region ( 2014-2024)
        1.4.2 Europe Status and Prospect ( 2014-2024)
        1.4.3 Middle East Status and Prospect ( 2014-2024)
        1.4.4 Africa Status and Prospect ( 2014-2024)
    1.5 EMEA Market Size (Value and Volume) of Multiple Sclerosis (MS) Drugs ( 2014-2024)
        1.5.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2024)
        1.5.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2024)

2 EMEA Multiple Sclerosis (MS) Drugs Competition by Manufacturers/Players/Suppliers, Region, Type and Application
    2.1 EMEA Multiple Sclerosis (MS) Drugs Market Competition by Players/Manufacturers
        2.1.1 EMEA Multiple Sclerosis (MS) Drugs Sales Volume and Market Share of Major Players ( 2014-2019)
        2.1.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Share by Players ( 2014-2019)
        2.1.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Players ( 2014-2019)
    2.2 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Type/Product Category
        2.2.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Type ( 2014-2019)
        2.2.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Type ( 2014-2019)
        2.2.3 EMEA Multiple Sclerosis (MS) Drugs Sale Price by Type ( 2014-2019)
    2.3 EMEA Multiple Sclerosis (MS) Drugs (Volume) by Application
    2.4 EMEA Multiple Sclerosis (MS) Drugs (Volume and Value) by Region
        2.4.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Market Share by Region ( 2014-2019)
        2.4.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Market Share by Region ( 2014-2019)
        2.4.3 EMEA Multiple Sclerosis (MS) Drugs Sales Price by Region ( 2014-2019)

3 Europe Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price), by Players, Countries, Type and Application
    3.1 Europe Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        3.1.1 Europe Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        3.1.2 Europe Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
    3.2 Europe Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
    3.3 Europe Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
    3.4 Europe Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
        3.4.1 Europe Multiple Sclerosis (MS) Drugs Sales Volume by Countries ( 2014-2019)
        3.4.2 Europe Multiple Sclerosis (MS) Drugs Revenue by Countries ( 2014-2019)
        3.4.3 Germany Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.4 France Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.5 UK Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.6 Russia Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.7 Italy Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        3.4.8 Benelux Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)

4 Middle East Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price), by Region, Type and Application
    4.1 Middle East Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        4.1.1 Middle East Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        4.1.2 Middle East Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
    4.2 Middle East Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
    4.3 Middle East Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
    4.4 Middle East Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
        4.4.1 Middle East Multiple Sclerosis (MS) Drugs Sales Volume by Countries ( 2014-2019)
        4.4.2 Middle East Multiple Sclerosis (MS) Drugs Revenue by Countries ( 2014-2019)
        4.4.3 Saudi Arabia Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.4 Israel Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.5 UAE Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        4.4.6 Iran Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)

5 Africa Multiple Sclerosis (MS) Drugs (Volume, Value and Sales Price) by Players, Countries, Type and Application
    5.1 Africa Multiple Sclerosis (MS) Drugs Sales and Value ( 2014-2019)
        5.1.1 Africa Multiple Sclerosis (MS) Drugs Sales Volume and Growth Rate ( 2014-2019)
        5.1.2 Africa Multiple Sclerosis (MS) Drugs Revenue and Growth Rate ( 2014-2019)
    5.2 Africa Multiple Sclerosis (MS) Drugs Sales and Market Share by Type
    5.3 Africa Multiple Sclerosis (MS) Drugs Sales and Market Share by Application
    5.4 Africa Multiple Sclerosis (MS) Drugs Sales Volume and Value (Revenue) by Countries
        5.4.1 Africa Multiple Sclerosis (MS) Drugs Sales Volume by Countries ( 2014-2019)
        5.4.2 Africa Multiple Sclerosis (MS) Drugs Revenue by Countries ( 2014-2019)
        5.4.3 South Africa Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.4 Nigeria Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.5 Egypt Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)
        5.4.6 Algeria Multiple Sclerosis (MS) Drugs Sales and Growth Rate ( 2014-2019)

6 EMEA Multiple Sclerosis (MS) Drugs Manufacturers/Players Profiles and Sales Data
    6.1 Bayer AG
        6.1.1 Company Basic Information, Manufacturing Base and Competitors
        6.1.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.1.2.1 Product A
            6.1.2.2 Product B
        6.1.3 Bayer AG Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.1.4 Main Business/Business Overview
    6.2 Bayhill Therapeutics
        6.2.1 Company Basic Information, Manufacturing Base and Competitors
        6.2.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.2.2.1 Product A
            6.2.2.2 Product B
        6.2.3 Bayhill Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.2.4 Main Business/Business Overview
    6.3 Biogen Idec
        6.3.1 Company Basic Information, Manufacturing Base and Competitors
        6.3.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.3.2.1 Product A
            6.3.2.2 Product B
        6.3.3 Biogen Idec Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.3.4 Main Business/Business Overview
    6.4 Cinnagen
        6.4.1 Company Basic Information, Manufacturing Base and Competitors
        6.4.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.4.2.1 Product A
            6.4.2.2 Product B
        6.4.3 Cinnagen Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.4.4 Main Business/Business Overview
    6.5 Daiichi Sankyo
        6.5.1 Company Basic Information, Manufacturing Base and Competitors
        6.5.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.5.2.1 Product A
            6.5.2.2 Product B
        6.5.3 Daiichi Sankyo Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.5.4 Main Business/Business Overview
    6.6 Eli Lilly
        6.6.1 Company Basic Information, Manufacturing Base and Competitors
        6.6.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.6.2.1 Product A
            6.6.2.2 Product B
        6.6.3 Eli Lilly Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.6.4 Main Business/Business Overview
    6.7 Fast Forward Llc
        6.7.1 Company Basic Information, Manufacturing Base and Competitors
        6.7.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.7.2.1 Product A
            6.7.2.2 Product B
        6.7.3 Fast Forward Llc Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.7.4 Main Business/Business Overview
    6.8 Antisense Therapeutics
        6.8.1 Company Basic Information, Manufacturing Base and Competitors
        6.8.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.8.2.1 Product A
            6.8.2.2 Product B
        6.8.3 Antisense Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.8.4 Main Business/Business Overview
    6.9 Apitope
        6.9.1 Company Basic Information, Manufacturing Base and Competitors
        6.9.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.9.2.1 Product A
            6.9.2.2 Product B
        6.9.3 Apitope Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.9.4 Main Business/Business Overview
    6.10 Five Prime Therapeutics
        6.10.1 Company Basic Information, Manufacturing Base and Competitors
        6.10.2 Multiple Sclerosis (MS) Drugs Product Type, Application and Specification
            6.10.2.1 Product A
            6.10.2.2 Product B
        6.10.3 Five Prime Therapeutics Multiple Sclerosis (MS) Drugs Sales, Revenue, Price and Gross Margin ( 2014-2019)
        6.10.4 Main Business/Business Overview
    6.11 Genmab
    6.12 Artielle Immunotherapeutics
    6.13 Genzyme
    6.14 Glaxosmithkline
    6.15 Gw Pharmaceuticals
    6.16 Innate Immunotherapeutics

7 Multiple Sclerosis (MS) Drugs Manufacturing Cost Analysis
    7.1 Multiple Sclerosis (MS) Drugs Key Raw Materials Analysis
        7.1.1 Key Raw Materials
        7.1.2 Price Trend of Key Raw Materials
        7.1.3 Key Suppliers of Raw Materials
        7.1.4 Market Concentration Rate of Raw Materials
    7.2 Proportion of Manufacturing Cost Structure
        7.2.1 Raw Materials
        7.2.2 Labor Cost
        7.2.3 Manufacturing Expenses
    7.3 Manufacturing Process Analysis of Multiple Sclerosis (MS) Drugs

8 Industrial Chain, Sourcing Strategy and Downstream Buyers
    8.1 Multiple Sclerosis (MS) Drugs Industrial Chain Analysis
    8.2 Upstream Raw Materials Sourcing
    8.3 Raw Materials Sources of Multiple Sclerosis (MS) Drugs Major Manufacturers  in 2018
    8.4 Downstream Buyers

9 Marketing Strategy Analysis, Distributors/Traders
    9.1 Marketing Channel
        9.1.1 Direct Marketing
        9.1.2 Indirect Marketing
        9.1.3 Marketing Channel Development Trend
    9.2 Market Positioning
        9.2.1 Pricing Strategy
        9.2.2 Brand Strategy
        9.2.3 Target Client
    9.3 Distributors/Traders List

10 Market Effect Factors Analysis
    10.1 Technology Progress/Risk
        10.1.1 Substitutes Threat
        10.1.2 Technology Progress in Related Industry
    10.2 Consumer Needs/Customer Preference Change
    10.3 Economic/Political Environmental Change

11 EMEA Multiple Sclerosis (MS) Drugs Market Forecast ( 2019-2025)
    11.1 EMEA Multiple Sclerosis (MS) Drugs Sales, Revenue and Price Forecast ( 2019-2025)
        11.1.1 EMEA Multiple Sclerosis (MS) Drugs Sales and Growth Rate Forecast ( 2019-2025)
        11.1.2 EMEA Multiple Sclerosis (MS) Drugs Revenue and Growth Rate Forecast ( 2019-2025)
        11.1.3 EMEA Multiple Sclerosis (MS) Drugs Price and Trend Forecast ( 2019-2025)
    11.2 EMEA Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.3 Europe Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.4 Middle Eastt Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.5 Africa Multiple Sclerosis (MS) Drugs Sales, Revenue and Growth Rate Forecast by Region ( 2019-2025)
    11.6 EMEA Multiple Sclerosis (MS) Drugs Sales Forecast by Type ( 2019-2025)
    11.7 EMEA Multiple Sclerosis (MS) Drugs Sales Forecast by Application ( 2019-2025)

12 Research Findings and Conclusion

13 Appendix
    13.1 Methodology/Research Approach
        13.1.1 Research Programs/Design
        13.1.2 Market Size Estimation
        13.1.3 Market Breakdown and Data Triangulation
    13.2 Data Source
        13.2.1 Secondary Sources
        13.2.2 Primary Sources
    13.3 Disclaimer